You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Globe 100

No. 8 overall | No. 2 biotech company

Biogen Idec beats the odds

Overcomes challenges to star again on Globe 100

Just a few years ago, the future looked uncertain for Biogen Idec Inc. .

Some thought its most profitable drug, Avonex, would gradually become obsolete as rivals developed their own products to treat multiple sclerosis. Its newer MS drug, Tysabri, was dogged by safety questions. And activist investor Carl Icahn was pushing hard for the company to be broken up or sold after years of unimpressive stock performance.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week